Literature DB >> 15845862

Interleukin-10-secreting "regulatory" T cells induced by glucocorticoids and beta2-agonists.

Emma J Peek1, David F Richards, Alexander Faith, Paul Lavender, Tak H Lee, Christopher J Corrigan, Catherine M Hawrylowicz.   

Abstract

Greater clinical benefit in controlling the symptoms of asthma is frequently observed through combining moderate doses of inhaled glucocorticoids together with long-acting beta(2)-agonists, as compared with increasing glucocorticoid dosage alone. To address in vitro whether glucocorticoids plus beta(2)-agonists, compared with glucocorticoids alone, have greater inhibitory activity on CD4+ T cell responses to allergen, peripheral blood CD4+ T cell responses to allergen were compared in the presence or absence of the glucocorticoid fluticasone proprionate and the short- and long-acting beta(2)-agonists salbutamol and salmeterol, respectively. Fluticasone proprionate inhibited interleukin (IL)-5 and IL-13 and enhanced IL-10 synthesis in allergen-stimulated cultures in a concentration-dependent manner. Salmeterol, but not salbutamol, inhibited IL-5 and IL-13 and enhanced IL-10 synthesis in these cultures. When used in combination the two drugs demonstrated an additive effect on this pattern of cytokine production. Allergen-specific T cell lines induced in the presence of salmeterol and fluticasone proprionate inhibited IL-5 and IL-13 production by allergen-specific Th2 cell lines in an IL-10-dependent manner. Thus fluticasone proprionate and salmeterol increased IL-10 and reduced Th2 cytokine synthesis additively in allergen stimulated human CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845862     DOI: 10.1165/rcmb.2005-0100OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  31 in total

1.  Regulatory T cells and regulation of allergic airway disease.

Authors:  Helen Martin; Christian Taube
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

Review 2.  Regulatory T cells in lung transplantation--an emerging concept.

Authors:  David C Neujahr; Christian P Larsen
Journal:  Semin Immunopathol       Date:  2011-03-20       Impact factor: 9.623

Review 3.  Regulatory T cells in human disease and their potential for therapeutic manipulation.

Authors:  Leonie S Taams; Donald B Palmer; Arne N Akbar; Douglas S Robinson; Zarin Brown; Catherine M Hawrylowicz
Journal:  Immunology       Date:  2006-05       Impact factor: 7.397

Review 4.  Interleukin-10-secreting regulatory T cells in allergy and asthma.

Authors:  Zoë Urry; Emmanuel Xystrakis; Catherine M Hawrylowicz
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

Review 5.  Glucocorticoids in T cell development, differentiation and function.

Authors:  Matthew D Taves; Jonathan D Ashwell
Journal:  Nat Rev Immunol       Date:  2020-11-04       Impact factor: 53.106

6.  The effects of tacrolimus ointment on regulatory T lymphocytes in atopic dermatitis.

Authors:  Marzia Caproni; Daniele Torchia; Emiliano Antiga; Walter Volpi; Elena del Bianco; Paolo Fabbri
Journal:  J Clin Immunol       Date:  2006-06-14       Impact factor: 8.317

Review 7.  The role of regulatory T cells in respiratory infections and allergy and asthma.

Authors:  Peter McGuirk; Sarah C Higgins; Kingston H G Mills
Journal:  Curr Allergy Asthma Rep       Date:  2010-01       Impact factor: 4.806

Review 8.  Pharmacological targeting of allergen-specific T lymphocytes.

Authors:  Peter A Tauber; Winfried F Pickl
Journal:  Immunol Lett       Date:  2017-03-18       Impact factor: 3.685

9.  Oral glucocorticoid treatment decreases interleukin-10 receptor expression on peripheral blood leucocyte subsets.

Authors:  M Moniuszko; A Bodzenta-Lukaszyk; M Dabrowska
Journal:  Clin Exp Immunol       Date:  2009-03-09       Impact factor: 4.330

Review 10.  Therapeutic manipulation of immune tolerance in allergic disease.

Authors:  Mübeccel Akdis; Cezmi A Akdis
Journal:  Nat Rev Drug Discov       Date:  2009-08       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.